Quiz

Article

NeurologyLive® Brain Games: October 6, 2024

Author(s):

Key Takeaways

  • NeurologyLive Brain Games offers weekly quizzes on diverse neurology topics, crafted by field experts.
  • Each quiz features three questions, focusing on areas like dementia, epilepsy, and movement disorders.
SHOW MORE

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on insomnia.

Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions on a variety of clinical and historical neurology topics, written by physicians, clinicians, and experts in the fields of neurological care and advocacy.

Test your mettle each week with 3 questions that cover a variety of aspects in the field of neurology, with a focus on dementia and Alzheimer disease, epilepsy and seizure disorders, headache and migraine, movement disorders, multiple sclerosis, neuromuscular disorders, sleep disorders, and stroke and cerebrovascular disease.

This week's questions include the theme of insomnia.

Click here to check out the prior iterations of Brain Games.

Interested in submitting quiz questions? Contact our editor, Marco Meglio, via email: mmeglio@neurologylive.com.

Which of the following is considered first-line therapy for chronic insomnia?


Which of the following neurotransmitters is most closely associated with wakefulness and is often targeted in pharmacological treatment of insomnia?


Which sleep stage is most likely to be disrupted in patients with insomnia?


How did you do on this week's quiz? Let us know with a response to the poll below. Don't forget to share and compare your results with your friends!

How many questions did you get correct?

One
Two
Three

Related Videos
Gil Rabinovici, MD
MaryAnn Mays, MD
Henri Ford, MD, MHA
Michael Levy, MD, PhD, is featured in this series.
David A. Hafler, MD, FANA
Lawrence Robinson, MD
© 2024 MJH Life Sciences

All rights reserved.